Clinical Papers

• Heart Outcomes Prevention Evaluation (HOPE) study
  
  Yusuf S et al. - N Engl J Med 2000 Jan 20; 342 (3): 145-53 Lancet 2000 - Jan 22; 355 (9200): 253-9
  
  
  
  
• Rosuvastatin is more effective than atorvastatin in the treatment of dyslipidaemic patients with the metabolic syndrome
  
  Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur Heart J. 2005 Sep 5; [Epub ahead of print].
  
  
  
  
• Is C-reactive protein a good predictor of cardiovascular events?
  
  Ridker et al N Engl J Med 2002 :347:1557-65
  
  
  
  
• Obese women have enhanced oxidant stress and platelet activation.
  
  Davi G et al Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002:288:2008-14
  
  
  
  
• How valid are the WHO and NCEP ATP-III definitions of the metabolic syndrome
  
  Laaksonen DE et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-7
  
  
  
  
• High density lipoprotein - guardian of the metabolic and vascular system?
  
  C Packard et al. High density lipoprotein: guardian of the metabolic and vascular system? International Journal of Clinical Practice 2002. 56: 761-772
  
  
  
  
• A universally accepted definition of the metabolic syndrome is needed
  
  Ford ES, et al. A Comparison of the Prevalence of the Metabolic Syndrome Using Two Proposed Definitions. Diabetes Care 2003 Mar; 26(3):575-581
  
  
  
  
• Statins modify the atherogenic lipid profile more favourably than fibrates
  
  Hippisley-Cox J, et al. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003; 326:689
  
  
  
  
• Rosuvastatin more effective at goal attainment than atorva-, simva-, and pravastatin
  
  Shepherd J, et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003; 91 (suppl):11C-19C
  
  
  
  
• Intensive statin therapy reduces markers of inflammation in ACS patients
  
  Kinlay S, et al. High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study. Circulation 2003; 108:1560–1566.
  
  
  
  

[next page]